Profile data is unavailable for this security.
About the company
Shenzhen Chipscreen Biosciences Co Ltd is a China-based company primarily engaged in the research, development, production and sales of original innovative pharmaceuticals. The products primarily include the epigenetic regulator Epidaza (chidamide), the insulin sensitizer Bilessglu (chiglitazar), the triple-pathway tumor inhibitor chiauranib, the small-molecule PD-L1 inhibitor CS23546, the brain-penetrating Aurora B selective inhibitor CS231295 and the highly selective small-molecule allosteric inhibitor CS32582 for tyrosine kinase 2 (TYK2). The Company is also engaged in the development of drugs such as CS1011, CS08399 and CS25141, as well as the licensing of research and development technologies. The Company primarily operates its businesses in the domestic market and overseas markets, including the United States.
- Revenue in CNY (TTM)850.99m
- Net income in CNY7.28m
- Incorporated2001
- Employees1.06k
- LocationShenzhen Chipscreen Biosciences Co Ltd21F-24F, Building B, Zhigu Industrial Park, Shuguang CommunSHENZHEN 518052ChinaCHN
- Phone+86 75 526952070
- Fax+86 75 526957291
- Websitehttps://www.chipscreen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayinglong Pharmaceutical Group Co Ltd | 3.77bn | 571.60m | 11.66bn | 2.65k | 20.39 | 2.71 | -- | 3.09 | 1.33 | 1.33 | 8.75 | 9.97 | 0.7211 | 6.23 | 11.99 | 1,421,812.00 | 11.38 | 10.77 | 13.82 | 13.35 | 46.77 | 42.40 | 15.78 | 14.39 | 4.58 | -- | 0.0226 | 37.31 | 18.85 | 6.62 | 19.14 | 7.97 | 34.47 | 18.98 |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 2.23bn | 617.04m | 11.82bn | 2.68k | 19.07 | 2.47 | -- | 5.31 | 1.42 | 1.42 | 5.11 | 10.93 | 0.3973 | 2.43 | 9.65 | 830,883.10 | 11.01 | 17.10 | 11.88 | 21.16 | 43.04 | 42.99 | 27.72 | 30.12 | 4.31 | -- | 0.0721 | 24.41 | 17.35 | 1.75 | 36.85 | -2.20 | 35.06 | -- |
| Beijing Foyou Pharma Co Ltd | 3.42bn | 463.07m | 12.17bn | 3.64k | 25.71 | 3.22 | -- | 3.56 | 0.9863 | 0.9863 | 7.28 | 7.87 | 0.733 | 3.27 | 9.59 | 938,316.50 | 9.99 | 12.53 | 12.82 | 17.64 | 65.17 | 68.01 | 13.62 | 13.02 | 2.52 | -- | 0.0077 | 33.16 | 3.17 | 7.28 | -0.0188 | 17.44 | 35.29 | -- |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.78bn | 799.61m | 12.18bn | 2.44k | 15.23 | 3.75 | -- | 3.22 | 1.41 | 1.41 | 6.67 | 5.73 | 0.711 | 1.89 | 8.06 | 1,553,625.00 | 15.08 | 11.90 | 25.52 | 18.89 | 79.26 | 74.36 | 21.21 | 16.46 | 0.9053 | -- | 0.1379 | 73.97 | 5.72 | 10.17 | 27.19 | 19.67 | 14.29 | 24.57 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.84bn | 546.80m | 12.36bn | 7.99k | 21.58 | 1.45 | -- | 1.26 | 0.4778 | 0.4778 | 8.61 | 7.10 | 0.623 | 3.08 | 5.32 | 1,230,310.00 | 3.48 | 2.33 | 5.81 | 4.32 | 46.64 | 41.26 | 5.58 | 3.99 | 0.6646 | 5.33 | 0.2803 | 29.47 | -5.65 | -2.44 | 745.24 | 45.22 | -26.03 | 33.24 |
| Shenzhen Chipscreen Biosciences Co Ltd | 850.99m | 7.28m | 12.98bn | 1.06k | 1,781.20 | 7.84 | -- | 15.25 | 0.0179 | 0.0179 | 2.09 | 4.06 | 0.2441 | 2.40 | 4.06 | 802,822.70 | 0.2089 | 0.0036 | 0.2479 | 0.0042 | 85.48 | 91.31 | 0.8557 | 0.0181 | 1.79 | -0.6319 | 0.4834 | 0.00 | 25.63 | 30.51 | -228.97 | -- | 15.08 | -- |
| Tibet Rhodiola Pharmaceutical Holding Co | 2.72bn | 981.20m | 13.45bn | 596.00 | 13.72 | 3.79 | -- | 4.95 | 3.04 | 3.04 | 8.44 | 11.02 | 0.5188 | 1.38 | 6.52 | 4,564,666.00 | 18.84 | 14.99 | 25.61 | 19.30 | 92.08 | 92.11 | 36.31 | 23.95 | 2.89 | -- | 0.1971 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 9.26bn | 930.27m | 14.26bn | 11.47k | 15.33 | 1.05 | -- | 1.54 | 0.6936 | 0.6936 | 6.91 | 10.17 | 0.4703 | 2.95 | 7.65 | 807,583.30 | 5.41 | 5.14 | 7.83 | 8.21 | 33.20 | 40.86 | 11.50 | 7.82 | 2.62 | -- | 0.003 | 20.02 | -9.38 | -2.16 | 56.62 | 10.55 | -11.46 | 24.57 |
Data as of Feb 13 2026. Currency figures normalised to Shenzhen Chipscreen Biosciences Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
5.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 9.06m | 2.20% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 2.68m | 0.65% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 1.85m | 0.45% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.68m | 0.41% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 1.62m | 0.39% |
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2025 | 1.23m | 0.30% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.13m | 0.27% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2025 | 821.70k | 0.20% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2025 | 754.02k | 0.18% |
| State Street Global Advisors Ltd.as of 31 Dec 2025 | 625.05k | 0.15% |
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
